Stock market data from financial platforms like Bloomberg or Yahoo Finance

Humacyte Receives FDA Approval for First-in-Class SYMVESS for Treatment of Extremity Vascular Trauma, Stock Surges 61%

Dec 20, 2024, 01:45 PM

Humacyte has received FDA approval for SYMVESS™, the first acellular tissue engineered vessel designed for the treatment of extremity vascular trauma. This innovative product serves as a bioengineered alternative to autologous vein grafts, aimed at improving outcomes in cases of limb-threatening vascular injuries where urgent revascularization is necessary and traditional grafts are not viable. The FDA's approval signifies a notable advancement in medical technology for patients requiring immediate vascular intervention. Following the announcement, Humacyte's stock price surged by approximately 61%, reflecting investor optimism about the product's potential impact in the medical field.